Trevi Therapeutics provided business updates ahead of its participation in the 14th Annual LifeSci Partners Corporate Access Event. The company announced that the last patient completed the Phase 2a RIVER trial in refractory chronic cough (RCC) in early January 2025.
Topline results for the RIVER trial continue to be expected in the first quarter of 2025. Additionally, approximately 80% of enrollment has been completed in the Phase 2b CORAL trial for idiopathic pulmonary fibrosis (IPF) patients with chronic cough.
Topline results for the CORAL trial are still expected in the first half of 2025. The company also reiterated the positive outcomes from its Human Abuse Potential study and the sample size re-estimation analysis of the CORAL trial, both achieved in late 2024.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.